KR20150010793A - 열 충격 단백질 (hsp) 90-베타의 조절에 의한 대사 증후군의 치료 방법들 - Google Patents

열 충격 단백질 (hsp) 90-베타의 조절에 의한 대사 증후군의 치료 방법들 Download PDF

Info

Publication number
KR20150010793A
KR20150010793A KR1020147035410A KR20147035410A KR20150010793A KR 20150010793 A KR20150010793 A KR 20150010793A KR 1020147035410 A KR1020147035410 A KR 1020147035410A KR 20147035410 A KR20147035410 A KR 20147035410A KR 20150010793 A KR20150010793 A KR 20150010793A
Authority
KR
South Korea
Prior art keywords
hsp90
metabolic syndrome
beta
expression
insulin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
KR1020147035410A
Other languages
English (en)
Korean (ko)
Inventor
니븐 라진 나레인
랑가프라사드 사란가라잔
비벡 케이. 비쉬누다스
은쉬엔 징
Original Assignee
버그 엘엘씨
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 버그 엘엘씨 filed Critical 버그 엘엘씨
Publication of KR20150010793A publication Critical patent/KR20150010793A/ko
Withdrawn legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A61K31/366—Lactones having six-membered rings, e.g. delta-lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/4155—1,2-Diazoles non condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/416—1,2-Diazoles condensed with carbocyclic ring systems, e.g. indazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/7056—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing five-membered rings with nitrogen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/713—Double-stranded nucleic acids or oligonucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/5308—Immunoassay; Biospecific binding assay; Materials therefor for analytes not provided for elsewhere, e.g. nucleic acids, uric acid, worms, mites
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/11—Antisense
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering nucleic acids [NA]
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/04—Endocrine or metabolic disorders
    • G01N2800/042—Disorders of carbohydrate metabolism, e.g. diabetes, glucose metabolism
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S977/00—Nanotechnology
    • Y10S977/902—Specified use of nanostructure
    • Y10S977/904—Specified use of nanostructure for medical, immunological, body treatment, or diagnosis
    • Y10S977/906—Drug delivery
    • Y10S977/907—Liposome

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Biophysics (AREA)
  • Wood Science & Technology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Urology & Nephrology (AREA)
  • Diabetes (AREA)
  • Analytical Chemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Pathology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Obesity (AREA)
  • Food Science & Technology (AREA)
  • Cell Biology (AREA)
  • General Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Gastroenterology & Hepatology (AREA)
KR1020147035410A 2012-05-25 2013-05-24 열 충격 단백질 (hsp) 90-베타의 조절에 의한 대사 증후군의 치료 방법들 Withdrawn KR20150010793A (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261652023P 2012-05-25 2012-05-25
US61/652,023 2012-05-25
PCT/US2013/042692 WO2013177535A2 (en) 2012-05-25 2013-05-24 Methods of treating a metabolic syndrome by modulating heat shock protein (hsp) 90-beta

Publications (1)

Publication Number Publication Date
KR20150010793A true KR20150010793A (ko) 2015-01-28

Family

ID=49624539

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020147035410A Withdrawn KR20150010793A (ko) 2012-05-25 2013-05-24 열 충격 단백질 (hsp) 90-베타의 조절에 의한 대사 증후군의 치료 방법들

Country Status (15)

Country Link
US (2) US9533002B2 (https=)
EP (1) EP2854865B1 (https=)
JP (1) JP6478908B2 (https=)
KR (1) KR20150010793A (https=)
CN (1) CN104812898B (https=)
AU (1) AU2013266086B2 (https=)
BR (1) BR112014029301A2 (https=)
CA (1) CA2874676A1 (https=)
EA (1) EA201492184A1 (https=)
HK (1) HK1209035A1 (https=)
IL (1) IL235910A0 (https=)
MX (1) MX2014014188A (https=)
NZ (1) NZ702169A (https=)
SG (1) SG11201407775WA (https=)
WO (1) WO2013177535A2 (https=)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2014014188A (es) * 2012-05-25 2015-05-11 Berg Llc Metodos para tratar un sindrome metaboilico mediante la modulacion de la proteina de choque termico (hsp) 90-beta.
RU2650646C2 (ru) 2012-09-27 2018-04-16 Дзе Чилдрен'З Медикал Сентер Корпорейшн Соединения, предназначенные для лечения ожирения, и способы их применения
CA3044998A1 (en) * 2014-03-26 2015-10-01 The Children's Medical Center Corporation Celastrol and derivatives for the treatment of obesity
US10023864B2 (en) 2014-06-06 2018-07-17 Berg Llc Methods of treating a metabolic syndrome by modulating heat shock protein (HSP) 90-beta
US10336768B2 (en) 2014-06-13 2019-07-02 Yuma Therapeutics, Inc. Pyrimidine compounds and methods using the same
WO2016149575A1 (en) * 2015-03-19 2016-09-22 Old Dominion University Synergistic regulated cell death induction with hsp90 inhibitors and nanosecond pulsed electric fields
JP7034078B2 (ja) * 2015-10-23 2022-03-11 イーアールエックス ファーマシューティカルズ インコーポレイテッド セラストロールの類似体
CN105920018B (zh) * 2016-06-15 2019-01-11 上海市内分泌代谢病研究所 雷公藤红素联合小檗碱制备治疗肥胖药物的用途
CN107543929A (zh) * 2016-06-23 2018-01-05 中国医学科学院肿瘤医院 基于蛋白标志物hsp90ab1诊断肺癌患者的试剂盒
CN107028953A (zh) * 2017-03-27 2017-08-11 北京大学 一种交感神经活性的刺激剂
SG10201913562VA (en) * 2017-04-24 2020-03-30 Samus Therapeutics Inc Hsp90 inhibitor oral formulations and related methods
US11379983B2 (en) 2017-06-23 2022-07-05 Nikon Corporation Analysis device, analysis program, and analysis method
CN112156188A (zh) * 2020-11-10 2021-01-01 上海交通大学医学院附属瑞金医院 Hsp90作为制备预防与治疗类固醇糖尿病药物的用途
CN113332308A (zh) * 2021-02-22 2021-09-03 广东省妇幼保健院 调控hsp90 b1表达量的制剂在制备预防或治疗多囊卵巢综合征药物中的应用
CN113160983A (zh) * 2021-04-09 2021-07-23 南京医科大学附属逸夫医院 一种代谢相关脂肪性肝病临床预测模型

Family Cites Families (57)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7078375B1 (en) 1996-10-25 2006-07-18 Peter Mose Larsen Diabetes-mediating proteins and therapeutic uses thereof
US20040048256A1 (en) 2001-09-07 2004-03-11 Agee Michele L. Novel proteins and nucleic acids encoding same
CA2501577A1 (en) 2002-10-07 2004-04-22 Antigenics, Inc. Heat shock protein binding fragments of cd91, and uses thereof
WO2004072081A1 (en) 2003-02-10 2004-08-26 Cellular Genomics, Inc. Certain 8-heteroaryl-6-phenyl-imidazo[1,2-a]pyrazines as modulators of kinase activity
GB0309637D0 (en) 2003-04-28 2003-06-04 Cancer Rec Tech Ltd Pyrazole compounds
EA009920B1 (ru) 2003-08-29 2008-04-28 Вернэлис (Кембридж) Лимитед Соединения пиримидотиофена
US20070249540A1 (en) 2004-05-24 2007-10-25 Adonia Papathanassiu Methods for Inhibiting Proteasome and Heat Shock Protein 90
AU2005274788A1 (en) * 2004-07-19 2006-02-23 University Of Rochester Biomarkers of neurodegenerative disease
US20060094682A1 (en) 2004-10-29 2006-05-04 Odyssey Thera, Inc. Kinase inhibitors for the treatment of diabetes and obesity
US9120774B2 (en) 2004-11-03 2015-09-01 University Of Kansas Novobiocin analogues having modified sugar moieties
FR2885904B1 (fr) 2005-05-19 2007-07-06 Aventis Pharma Sa Nouveaux derives du fluorene, compositions les contenant et utilisation
JP2009504673A (ja) 2005-08-11 2009-02-05 ノバルティス アクチエンゲゼルシャフト ピリミジルアミノベンズアミド化合物であるタンパク質キナーゼ阻害剤および１７−ａａｇのようなｈｓｐ９０阻害剤を含む組合せ
US20070207950A1 (en) 2005-12-21 2007-09-06 Duke University Methods and compositions for regulating HDAC6 activity
WO2007077042A1 (en) 2006-01-06 2007-07-12 Topotarget Switzerland Sa New method for the treatment of gout or pseudogout
WO2007097839A2 (en) 2006-02-16 2007-08-30 Massachusetts Eye And Ear Infirmary Ansamycin analogs or heat shock 90 inhibitors in combination with pdt treatin conditions of the eye
CA2645930A1 (en) 2006-03-17 2007-09-27 Crossbeta Biosciences B.V. Methods of binding of cross-beta structures by chaperones
CA2653052A1 (en) 2006-05-19 2007-11-29 The Scripps Research Institute Treatment of protein misfolding
CA2653222A1 (en) 2006-05-25 2007-12-06 Synta Pharmaceuticals Corp. Triazole compounds that modulate hsp90 activity
WO2008024974A1 (en) 2006-08-24 2008-02-28 Serenex, Inc. Pyrimidine and pyrazine derivatives
JP2010501593A (ja) 2006-08-24 2010-01-21 セレネックス， インコーポレイテッド イソキノリン、キナゾリンおよびフタラジン誘導体
JP5518478B2 (ja) 2006-10-12 2014-06-11 アステックス、セラピューティックス、リミテッド 医薬化合物
EP2073802A1 (en) 2006-10-12 2009-07-01 Astex Therapeutics Limited Pharmaceutical combinations
GB0620259D0 (en) * 2006-10-12 2006-11-22 Astex Therapeutics Ltd Pharmaceutical compounds
GB0622084D0 (en) 2006-11-06 2006-12-13 Chroma Therapeutics Ltd Inhibitors of HSP90
BRPI0718562A2 (pt) 2006-11-09 2014-04-08 Biotica Tech Ltd Composto, processo para preparar e para gerar análogo de macbecina, análogo de macbecina, composição farmacêutica, uso do análogo de macbecina, e, cepa engenheirada.
CN101688227B (zh) 2007-01-26 2013-07-24 科森生物科学公司 通过工程化生物合成制备的大环内酰胺
JP5401329B2 (ja) 2007-03-20 2014-01-29 キュリス，インコーポレイテッド Ｈｓｐ９０インヒビターとしての縮合アミノピリジン
GB2449293A (en) 2007-05-17 2008-11-19 Evotec Compounds having Hsp90 inhibitory activity
WO2008151833A2 (en) 2007-06-13 2008-12-18 Hochschule Mannheim Compounds for the modulation of huntingtin aggregation, methods and means for identifying such compounds
IL184671A0 (en) 2007-07-17 2008-12-29 Hadasit Med Res Service Substances directed to heparanase c-terminal domain-or substance derived therefrom and uses thereof as modulators of heparanas biological activities
DE102007041116A1 (de) 2007-08-30 2009-03-05 Merck Patent Gmbh 1,3-Dihydro-isoindolderivate
TW200920357A (en) 2007-09-10 2009-05-16 Curis Inc HSP90 inhibitors containing a zinc binding moiety
EP2060565A1 (en) 2007-11-16 2009-05-20 4Sc Ag Novel bifunctional compounds which inhibit protein kinases and histone deacetylases
WO2009067245A2 (en) 2007-11-20 2009-05-28 University Of Florida Research Foundation, Inc. Compositions and methods for tissue repair
EP2226632B1 (en) 2007-12-28 2014-02-12 Takeda Pharmaceutical Company Limited Method for screening of cell-protecting agent
JP5509100B2 (ja) 2008-03-07 2014-06-04 アジェンデ・キミケ・リウニテ・アンジェリニ・フランチェスコ・ア・チ・エレ・ア・エフェ・ソシエタ・ペル・アチオニ 新規な１−ベンジル−３−ヒドロキシメチルインダゾール誘導体及びそのＭＣＰ−１，ＣＸ３ＣＲ１及びｐ４０の発現に基づく疾病の治療への使用
WO2009114470A2 (en) 2008-03-10 2009-09-17 Curis, Inc. Tetrahydroindole and tetrahdyroindazole as hsp90 inhibitors containing a zinc binding moiety
EP2100879A1 (en) 2008-03-13 2009-09-16 4Sc Ag Novel N-substituted tetrahydroisoquinoline/isoindoline hydroxamic acid compounds
BRPI0822354B1 (pt) 2008-05-19 2020-11-10 Hewlett Packard Development Company, L.P método para suportar login de pré-boot em sistemas de computador, mídia legível por computador e sistema de computador
US8119637B2 (en) 2008-06-10 2012-02-21 Plexxikon Inc. Substituted pyrrolo[2,3-b]pyrazines and methods for kinase modulation, and indications therefor
US20100022635A1 (en) 2008-07-28 2010-01-28 University Of Kansas Heat shock protein 90 inhibitor dosing methods
WO2010015617A1 (en) 2008-08-04 2010-02-11 Dsm Ip Assets B.V. Process for producing carnosol from carnosic acid using hydrogen peroxide or peracids
WO2010019965A1 (en) 2008-08-15 2010-02-18 The Board Of Trustees Of The Leland Stanford Junior University Compositions and methods for modulating epsilon protein kinase c-mediated cytoprotection
US20110230551A1 (en) 2008-09-15 2011-09-22 Leslie Gunatilaka Withaferin a analogs and uses thereof
CN105727297A (zh) 2008-11-28 2016-07-06 诺华股份有限公司 包含hsp90抑制剂和mtor抑制剂的药物组合
TW201102391A (en) 2009-03-31 2011-01-16 Biogen Idec Inc Certain substituted pyrimidines, pharmaceutical compositions thereof, and methods for their use
JP2013516442A (ja) * 2010-01-07 2013-05-13 アクロン・モレキュールズ・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング 肥満症に用いる小分子
US20110201587A1 (en) * 2010-02-16 2011-08-18 Bio Holding, Inc. Hsp90 inhibitors and methods of use
CN102753546A (zh) 2010-02-17 2012-10-24 日东制药株式会社 新型5-元杂环衍生物及其制备方法
CA2697887A1 (en) 2010-03-12 2011-09-12 Institut De Recherches Cliniques De Montreal Modulating and/or detecting activation induced deaminase and methods of use thereof
WO2011133659A2 (en) 2010-04-20 2011-10-27 Emory University Inhibitors of hif and angiogenesis
US8598339B2 (en) 2011-02-01 2013-12-03 University Of Kansas Withanolide isolated from Physalis longifolia and analogs and methods of use thereof
WO2012106343A2 (en) 2011-02-01 2012-08-09 The Board Of Trustees Of The University Of Illinois Hdac inhibitors and therapeutic methods using the same
WO2012139010A1 (en) 2011-04-08 2012-10-11 University Of Kansas Grp94 inhibitors
WO2013015661A2 (en) 2011-07-28 2013-01-31 Ildong Pharm Co.,Ltd. Novel prodrugs of 5-(2,4-dihydroxy-5-isopropylphenyl)-n-ethyl-4-(5-methyl1-1,2,4-oxadiazol-3-yl)isoxazole-3-carboxamide
MX2014014188A (es) * 2012-05-25 2015-05-11 Berg Llc Metodos para tratar un sindrome metaboilico mediante la modulacion de la proteina de choque termico (hsp) 90-beta.
CN102772399A (zh) * 2012-08-16 2012-11-14 厦门大学 藤黄酸作为5`-amp激活的蛋白激酶激动剂的用途

Also Published As

Publication number Publication date
EP2854865B1 (en) 2019-02-20
US20170166891A1 (en) 2017-06-15
MX2014014188A (es) 2015-05-11
EP2854865A4 (en) 2016-03-02
EA201492184A1 (ru) 2015-07-30
BR112014029301A2 (pt) 2017-07-25
AU2013266086A1 (en) 2014-12-11
JP6478908B2 (ja) 2019-03-06
WO2013177535A3 (en) 2015-03-05
SG11201407775WA (en) 2014-12-30
US9533002B2 (en) 2017-01-03
HK1209035A1 (en) 2016-03-24
NZ702169A (en) 2016-10-28
CA2874676A1 (en) 2013-11-28
WO2013177535A2 (en) 2013-11-28
WO2013177535A8 (en) 2014-11-13
CN104812898B (zh) 2018-01-30
IL235910A0 (en) 2015-01-29
CN104812898A (zh) 2015-07-29
EP2854865A2 (en) 2015-04-08
JP2015520170A (ja) 2015-07-16
AU2013266086B2 (en) 2018-03-01
US20140154266A1 (en) 2014-06-05

Similar Documents

Publication Publication Date Title
EP2854865B1 (en) Methods of treating a metabolic syndrome by modulating heat shock protein (hsp) 90-beta
Liu et al. NR1D1 modulates synovial inflammation and bone destruction in rheumatoid arthritis
Sasako et al. Hepatic Sdf2l1 controls feeding-induced ER stress and regulates metabolism
Luo et al. AMPK activation by metformin suppresses abnormal extracellular matrix remodeling in adipose tissue and ameliorates insulin resistance in obesity
García‐Rúa et al. Endolysosomal two‐pore channels regulate autophagy in cardiomyocytes
Lu et al. Troxerutin counteracts domoic acid–induced memory deficits in mice by inhibiting CCAAT/enhancer binding protein β–mediated inflammatory response and oxidative stress
Raun et al. Rac1 muscle knockout exacerbates the detrimental effect of high‐fat diet on insulin‐stimulated muscle glucose uptake independently of Akt
Douglass et al. Obesity-associated microglial inflammatory activation paradoxically improves glucose tolerance
Li et al. Homozygous receptors for insulin and not IGF-1 accelerate intimal hyperplasia in insulin resistance and diabetes
Zhao et al. Serum response factor induces endothelial-mesenchymal transition in glomerular endothelial cells to aggravate proteinuria in diabetic nephropathy
Ding et al. Norathyriol reverses obesity-and high-fat-diet-induced insulin resistance in mice through inhibition of PTP1B
Lounev et al. Matrix metalloproteinase-9 deficiency confers resilience in fibrodysplasia ossificans progressiva in a man and mice
Zhao et al. Crucial role of serum response factor in renal tubular epithelial cell epithelial-mesenchymal transition in hyperuricemic nephropathy
Xu et al. ECSIT is a critical limiting factor for cardiac function
Wu et al. PAK4 phosphorylates and inhibits AMPKα to control glucose uptake
Tie et al. CCAAT/enhancer‐binding protein β overexpression alleviates myocardial remodelling by regulating angiotensin‐converting enzyme‐2 expression in diabetes
KR101910770B1 (ko) Dscr1-4 를 이용한 제2형 당뇨병 치료제의 스크리닝 방법, 및 제2형 당뇨병 진단 또는 예후 예측용 조성물
Guo et al. Sirt1 activation prevents high glucose-induced angiotensin converting enzyme 2 downregulation in renal tubular cells by regulating the TIMP3/ADAM17 pathway
Cao et al. ACSL1: A preliminary study that provides a new target for the treatment of renal fibrosis could bring new insights in diabetic kidney disease
Herrera-Ojeda et al. The pathophysiological link between type 1 diabetes and MASLD: insights into insulin resistance and liver dysfunction
Yuan et al. Activin A activation drives renal fibrosis through the STAT3 signaling pathway
Pittala et al. G12/13-mediated signaling stimulates hepatic glucose production and has a major impact on whole body glucose homeostasis
TWI359271B (en) Pharmaceutical composition for insulin resistance
US20150018383A1 (en) Biomarkers of renal disorders
Shokri et al. Heparin suppresses FoxO1/pFoxO1 signaling axis in vascular smooth muscle cells

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20141217

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
PC1203 Withdrawal of no request for examination
WITN Application deemed withdrawn, e.g. because no request for examination was filed or no examination fee was paid